Product Highlight - Stelara
09 Jun 2023
The only IL-12/23 biologics for Inflammatory Bowel Disease1
STELARA® provides sustained remission for both Crohn’s Disease (CD) and Ulcerative Colitis (UC) patients 2,3
• Rapid clinical response in 3 weeks and clinical remission in 8 weeks by only 1 intravenous (IV) infusion for CD 4
• 5 years sustained remission for CD 2 and over 3 years sustained remission data for UC 3
• Mere to placebo safety profile 4,5 with no increased risk of tuberculosis reactivation and malignancy 2,5
• Only once IV induction 6 and 90 mg subcutaneous (SC) injection at week 8 followed by every 12 weeks 90 mg SC maintenance 7
References:
1. Brownstone ND, et al. (2021). Biologics: Targets and Therapy, 39-51. 2. Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. 3. Abreu MT, et al. J Crohns Colitis. 2022 Mar3 [Online ahead of print]. 4. Feagan BG, et al. N Engl J Med. 2016;375(20):1946-1960. 5. Abreu MT, et al. J Crohns Colitis. 2021; 15:S113-S115. 6. STELARA®IV Hong Kong Prescribing Information P05. 7. STELARA® Hong Kong Prescribing Information P09.
JANSSEN, A DIVISION OF JOHNSON & JOHNSON HK LTD
13/F, Tower 1, Grand Century Place, 193 Prince Edward Rd West, Mongkok
Tel: (+852) 2736 1711 • Fax: (+852) 2736 1926
STELARA® provides sustained remission for both Crohn’s Disease (CD) and Ulcerative Colitis (UC) patients 2,3
• Rapid clinical response in 3 weeks and clinical remission in 8 weeks by only 1 intravenous (IV) infusion for CD 4
• 5 years sustained remission for CD 2 and over 3 years sustained remission data for UC 3
• Mere to placebo safety profile 4,5 with no increased risk of tuberculosis reactivation and malignancy 2,5
• Only once IV induction 6 and 90 mg subcutaneous (SC) injection at week 8 followed by every 12 weeks 90 mg SC maintenance 7
References:
1. Brownstone ND, et al. (2021). Biologics: Targets and Therapy, 39-51. 2. Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. 3. Abreu MT, et al. J Crohns Colitis. 2022 Mar3 [Online ahead of print]. 4. Feagan BG, et al. N Engl J Med. 2016;375(20):1946-1960. 5. Abreu MT, et al. J Crohns Colitis. 2021; 15:S113-S115. 6. STELARA®IV Hong Kong Prescribing Information P05. 7. STELARA® Hong Kong Prescribing Information P09.
JANSSEN, A DIVISION OF JOHNSON & JOHNSON HK LTD
13/F, Tower 1, Grand Century Place, 193 Prince Edward Rd West, Mongkok
Tel: (+852) 2736 1711 • Fax: (+852) 2736 1926
